MOMA Therapeutics
MA - CambridgeBiotechnology
Focus: MOMA Therapeutics is an early-stage biotech company focused on enzyme and molecular machine-based therapeutics for oncology. Currently in Series B funding with a pre-clinical to Phase 1 pipeline and no approved products.
Profile data last refreshed 2d ago · AI intelligence enriched 1w ago
Funding Stage
SERIES B
Open Jobs
0
About MOMA Therapeutics
AI assessmentNot HiringNo open roles listed right now. Follow MOMA Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
2 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
MOMA-313
Advanced Solid TumorClinical Trials (1)
NCT06545942Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
Phase 1Help build intelligence for MOMA Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.